Clinical Edge Journal Scan

Weight change influences hip fracture risk in T2D


 

Key clinical point: Body weight gain and loss are significantly associated with a higher risk for hip fracture in patients with type 2 diabetes (T2D), irrespective of the body mass index.

Major finding: Compared with stable weight, body weight loss of ≥10% (adjusted hazard ratio [aHR] 1.605; 95% CI 1.493-1.725) and 5%-10% (aHR 1.237; 95% CI 1.177-1.300) and gain of ≥10% (aHR 1.457; 95% CI 1.318-1.612) and 5%-≤10% (aHR 1.234; 95% CI 1.156-1.318) were associated with a higher risk for hip fracture.

Study details: Findings are from a nationwide cohort study including 1,447,579 patients aged >40 years with T2D who reported 11,848 hip fracture events.

Disclosures: The study was supported by a National Research Foundation of Korea grant funded by the Korean government. The authors declared no conflicts of interest.

Source: Lee SW et al. Weight change and the risk of hip fractures in patients with type 2 diabetes: A nationwide cohort study. Osteoporos Int. 2022 (Apr 19). Doi: 10.1007/s00198-022-06398-8

Recommended Reading

Advice from the Trenches on Type 2 Diabetes Care
Type 2 Diabetes ICYMI
Tirzepatide (Mounjaro) approved for type 2 diabetes
Type 2 Diabetes ICYMI
Pancreatic involvement in COVID-19: What do we know?
Type 2 Diabetes ICYMI
Does COVID-19 raise the risk for diabetes?
Type 2 Diabetes ICYMI
Newly approved tirzepatide’s retail price announced
Type 2 Diabetes ICYMI
T2D: Superior glycemic control with once-weekly tirzepatide vs. insulin degludec
Type 2 Diabetes ICYMI
Severe hypoglycemia raises the risk for QTc prolongation in T2D
Type 2 Diabetes ICYMI
T2D: Adding Gla-300 to GLP-1 RA improves glycemic control in real world
Type 2 Diabetes ICYMI
Prolonged proton pump inhibitor therapy raises the risk for T2D
Type 2 Diabetes ICYMI
Quadruple therapy as attractive as once-weekly GLP-1RA therapy in poorly controlled T2D
Type 2 Diabetes ICYMI